NATUS MEDICAL INC Form 10-Q August 06, 2010 Table of Contents

## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **FORM 10-Q**

# x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2010

" TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-33001

# NATUS MEDICAL INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of

incorporation or organization)

1501 Industrial Road, San Carlos, CA 94070

(Address of principal executive offices) (Zip Code)

77-0154833

(I.R.S. Employer

**Identification No.)** 

#### (650) 802-0400

(Registrant s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes "No"

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

 Large Accelerated filer
 "
 Accelerated filer
 x

 Non-accelerated filer
 " (Do not check if a smaller reporting company)
 Smaller reporting company
 "

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 Yes " No x
 No x

The number of issued and outstanding shares of the registrant s Common Stock, \$0.001 par value, as of August 2, 2010 was 28,859,510.

#### NATUS MEDICAL INCORPORATED

#### TABLE OF CONTENTS

PART I.	FINANCIAL INFORMATION	Page No. 3
Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets as of June 30, 2010 and December 31, 2009 (unaudited)	3
	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2010 and 2009 (unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2010 and 2009 (unaudited)	5
	Notes to Condensed Consolidated Financial Statements (unaudited)	6
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	22
Item 4.	Controls and Procedures	23
PART II.	OTHER INFORMATION	23
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 6.	Exhibits	32
<u>Signatures</u>		33

#### PART I. FINANCIAL INFORMATION

#### Item 1. Financial Statements

#### NATUS MEDICAL INCORPORATED AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

#### (in thousands, except share amounts)

ASSETS Current assets: Cash and cash equivalents \$38,956 \$38,956 \$38	32,586 965 43,750 22,408 4,213 4,248
	965 43,750 22,408 4,213
	965 43,750 22,408 4,213
	965 43,750 22,408 4,213
Short-term investments 946	43,750 22,408 4,213
	22,408 4,213
	4,213
	4.240
	.,
Total current assets112,28810	08,170
Property and equipment, net 15,417 1	14,066
	70,144
	92,258
,	6,853
	,
Total assets \$292,484 \$ 29	91,491
LIABILITIES AND STOCKHOLDERS EQUITY	
Current liabilities:	
	11,074
Current portion of long-term debt 178	178
	17,245
	4,705
	,
Total current liabilities 29,126 3	33,202
Long-term liabilities:	
Long-term debt 842	931
	7,186
	7,016
	.,
Total liabilities 43,578 4	48,335
	+0,555
Stockholders equity:	
Common Stock, \$0.001 par value, 120,000,000 shares authorized; shares issued and outstanding 28,826,248 in	
•	50,374
	5,737
	12,955)

Total stockholders equity	248,906	243,156
Total liabilities and stockholders equity	\$ 292,484	\$ 291,491

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

#### NATUS MEDICAL INCORPORATED AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

#### (in thousands, except per share amounts)

	Jun	nths Ended e 30,	Six Montl June	30,
	2010	2009	2010	2009
Revenue	\$ 52,697	\$ 37,263	\$ 101,857	\$ 70,620
Cost of revenue	21,575	14,370	41,123	27,419
Gross profit	31,122	22,893	60,734	43,201
Operating expenses:	12 501	10.051	07.054	20.229
Marketing and selling	13,581	10,251	27,354	20,238
Research and development	5,238	3,950	10,368	7,664
General and administrative	7,791	5,270	18,708	10,774
Total operating expenses	26,610	19,471	56,430	38,676
Income from operations	4,512	3,422	4,304	4,525
Other income, net	240	387	186	513
Income before provision for income tax	4,752	3,809	4,490	5,038
Provision for income tax	1,647	1,473	1,688	1,915
Net income	\$ 3,105	\$ 2,336	\$ 2,802	\$ 3,123
Earnings per share:				
Basic	\$ 0.11	\$ 0.08	\$ 0.10	\$ 0.11
				+ ••••
Diluted	\$ 0.11	\$ 0.08	\$ 0.10	\$ 0.11
Weighted average shares used in the calculation of earnings per share:				
Basic	27,809	27,644	27,755	27,625
Diluted	29,110	28,276	28,956	28,208

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

#### NATUS MEDICAL INCORPORATED AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

#### (in thousands)

		Six Months Ended June 30,	
	2010	2009	
Operating activities:			
Net income	\$ 2,802	\$ 3,123	
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	4,262	4,440	
Accounts receivable reserves	(24)	1,331	
Warranty reserves	86	639	
Loss on disposal of property and equipment	25		
Share-based compensation	2,330	1,773	
Excess tax benefits on the exercise of options	(779)	(12)	
Impairment of intangible assets	300		
Changes in operating assets and liabilities:			
Accounts receivable	5,353	893	
Inventories	(3,625)	987	
Prepaid expenses and other assets	136	564	
Accounts payable	(1,475)	6	
Deferred income tax	68	0	
Accrued liabilities and deferred revenue	(2,772)	163	
	(2,772)	105	
Net cash provided by operating activities	6,687	13,907	
Investing activities:			
Cash paid for business acquisitions and earn out obligations, net of cash acquired	(19)	(998)	
Purchases of property and equipment	(2,052)	(2,080)	
Capitalized software development costs	(161)	(377)	
Purchases of marketable securities	(975)	(866)	
Sales of marketable securities	975		
Net cash used in investing activities	(2,232)	(4,321)	
Financing activities:			
Proceeds from stock option exercises and ESPP purchases	2,007	414	
Excess tax benefits on the exercise of options	779	12	
Payments on borrowings	(89)	(89)	
Net cash provided by financing activities	2,697	337	
Exchange rate effect on cash and cash equivalents	(782)	845	
	( 250	10.769	
Net increase in cash and cash equivalents	6,370	10,768	
Cash and cash equivalents, beginning of period	32,586	56,915	
Cash and cash equivalents, end of period	\$ 38,956	\$ 67,683	
Supplemental disclosure of cash flow information:			

## Edgar Filing: NATUS MEDICAL INC - Form 10-Q

Cash paid for income taxes \$ 2,635 \$	129
Non-cash investing activities:         Acquisition-related earn out obligations included in accrued liabilities         \$	19

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

#### NATUS MEDICAL INCORPORATED AND SUBSIDIARIES

#### NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

#### 1 - Basis of Presentation

The accompanying interim condensed consolidated financial statements of Natus Medical Incorporated (Natus, we, us, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). Except as updated below, the accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the consolidated financial statements included in the Company s Annual Report on Form 10-K for the year ended December 31, 2009.

Interim financial reports are prepared in accordance with the rules and regulations of the Securities and Exchange Commission; accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. The interim financial information is unaudited, but reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations, and cash flows for the interim periods presented. Operating results for the three and six months ended June 30, 2010 are not necessarily indicative of the results that may be expected for the year ending December 31, 2010. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

#### **Comprehensive Income**

Comprehensive income is comprised of net income and gains or losses resulting from currency translations of foreign investments. The details of comprehensive income are as follows (in thousands):

Three	Months	Six Months		
E	nded	Ended		
June 30,		June 30,		
2010	2009	2010	2009	